HCPCS M0238: Tocilizumab Intravenous Infusion for Hospitalized COVID-19 Adults - OpenPayer

Summary & Overview

HCPCS M0238: Tocilizumab Intravenous Infusion for Hospitalized COVID-19 Adults

HCPCS Level II code M0238 denotes the intravenous infusion of tocilizumab-anoh as a second dose for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. The code bundles the infusion and post-administration monitoring for the second dose. This code matters nationally as tocilizumab and similar immune-modulating therapies have been integral to hospital treatment protocols for severe COVID-19 and are subject to evolving coverage and payment policies.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of tocilizumab-anoh in hospitalized adults, typical sites of service, and the service type reflected by this HCPCS Level II code. The publication also outlines payer coverage considerations and common billing practices tied to this service, including recognized modifiers. Additionally, the analysis highlights benchmarks and policy updates relevant to hospital infusion billing and reimbursement for COVID-19 therapeutics where available.

The content is intended for national audiences including hospital billing managers, compliance officers, and policy analysts seeking a clear, single-source reference for HCPCS Level II code M0238 and its role in inpatient COVID-19 care.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareM0238HCPCS Level IItocilizumabintravenous infusionhospital inpatientCOVID-19 therapeuticsinfusion monitoringsecond doserespiratory support

Billing Code Overview

HCPCS Level II code M0238 describes an intravenous infusion of tocilizumab-anoh administered as a second dose for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The code includes the infusion and post-administration monitoring associated with the second dose.

Service type: Intravenous therapeutic infusion of a monoclonal antibody for inpatient management of severe COVID-19
Typical site of service: Hospital inpatient setting (including intensive care units) for adults requiring advanced respiratory support

Clinical & Coding Specifications

Clinical Context

A hospitalized adult patient with severe COVID-19 pneumonia is receiving systemic corticosteroids and requires supplemental oxygen delivered by high-flow nasal cannula. The patient has progressive hypoxemia and increasing inflammatory markers (elevated CRP, ferritin) despite standard care. The inpatient medicine team, in coordination with critical care, reviews eligibility for IL-6 receptor antagonist therapy. After verifying indications and contraindications (no active serious bacterial infection, acceptable liver function, and platelet count), the pharmacy prepares an IV dose of tocilizumab-anoh. Nursing administers the infusion in the inpatient unit with continuous pulse oximetry and cardiac monitoring as clinically indicated. The service includes the initial infusion and post-administration monitoring; a second dose is given per protocol if the patient’s condition warrants and per the billing descriptor. Documentation includes indication, baseline vitals and labs, informed consent, drug lot and dose, infusion start/stop times, tolerance, and any adverse reactions. Typical sites of service are the inpatient ward, step-down unit, or intensive care unit, and the service is billed using M0238 with appropriate modifier when required.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard billing	Use when no special circumstances apply and the service is billed as routine.

HCPCS M0249: Tocilizumab IV Infusion for Hospitalized COVID-19 Patients, First Dose

HCPCS-M0241-CASIRIVIMAB-IMDEVIMAB-HOME-INFUSION-INJECTION-MONITORING

HCPCS M0241: Casirivimab and Imdevimab Administration with Home Monitoring

HCPCS-M0223-BEBTELOVIMAB-INTRAVENOUS-INJECTION-HOME-MONITORING

HCPCS M0223: Bebtelovimab IV Injection with Home Monitoring

HCPCS-M0248-SOTROVIMAB-INFUSION-HOME-ADMINISTRATION

HCPCS M0248: Intravenous Sotrovimab Infusion, Home Administration

HCPCS-M0233-TOCILIZUMAB-INFUSION-COVID19-HOSPITALIZED-ADULTS

HCPCS Level II M0233: Tocilizumab Intravenous Infusion, First Dose for Hospitalized Adults

HCPCS-M0234-TOCILIZUMAB-INFUSION-HOSPITALIZED-COVID19

HCPCS Level II M0234: Tocilizumab-aazg IV Infusion, Second Dose

HCPCS-M0237-TOCILIZUMAB-INFUSION-COVID19-HOSPITALIZED-ADULT-FIRST-DOSE

HCPCS Level II M0237: Intravenous Tocilizumab-anoh Infusion, First Dose

HCPCS-M0239-INTRAVENOUS-BAMLANIVIMAB-INFUSION-WITH-MONITORING

HCPCS M0239: Intravenous Infusion of Bamlanivimab with Monitoring

HCPCS-M0247-SOTROVIMAB-INTRAVENOUS-INFUSION-WITH-MONITORING

HCPCS M0247: Intravenous Infusion of Sotrovimab, Includes Monitoring

HCPCS-M0301-FABRIC-WRAPPING-ABDOMINAL-ANEURYSM

HCPCS M0301: Fabric Wrapping of Abdominal Aneurysm

Showing 1–10 of 27

Taxonomy Code	Specialty	Notes
207RH0000X	Internal Medicine	Hospitalists commonly order and document tocilizumab for eligible inpatients.
208000000X	General Practice	May be involved in inpatient management in some hospital settings.
2084P0800X	Pulmonary Disease	Pulmonary/critical care physicians frequently manage respiratory failure and direct biologic therapy in COVID-19.
207K00000X	Emergency Medicine	Emergency physicians may initiate treatment for admitted patients during early hospitalization.
208800000X	Critical Care Medicine	Intensivists oversee dosing and monitoring for patients on high-flow oxygen, NIV, IMV, or ECMO.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J12.82`	Pneumonia due to coronavirus disease 2019	Primary pulmonary diagnosis indicating COVID-19 pneumonia requiring advanced therapies.
`U07.1`	COVID-19	Confirms SARS-CoV-2 infection as the etiologic cause prompting tocilizumab use in severe cases.
`J80`	Acute respiratory distress syndrome	Applicable for patients on invasive ventilation or ECMO where IL-6 blockade may be considered as part of escalation.
`J96.01`	Acute respiratory failure with hypoxia	Captures the respiratory failure state requiring supplemental oxygen and advanced respiratory support.
`R09.02`	Hypoxemia	Indicates low oxygen saturation supporting the requirement for supplemental oxygen and eligibility for therapy.
`D65`	Disseminated intravascular coagulation (DIC)	Monitors contraindication/complication considerations; tocilizumab use requires evaluation of coagulopathy risk.
`K72.90`	Acute and chronic liver failure without coma, unspecified	Significant hepatic dysfunction that impacts safety and dosing considerations for immunomodulatory therapy.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug	Used for IV administration techniques and monitoring when infusion time and observation align with chemotherapy/biologic infusion coding conventions.
`96415`	Chemotherapy administration, IV infusion technique; each additional hour (List separately in addition to code for primary infusion)	Used if infusion monitoring extends beyond the initial hour and facility billing follows infusion time-based add-on reporting.
`96365`	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	May be reported for simple IV infusion services in some billing workflows when specific biologic administration codes are not applicable; facility-dependent.
`99231`	Subsequent hospital care, per day, for evaluation and management	Represents daily inpatient evaluation by the admitting or consulting physician and commonly accompanies biologic administration during hospitalization.
`36415`	Collection of venous blood by venipuncture	Used for laboratory monitoring before and after tocilizumab infusion (e.g., liver enzymes, CBC, inflammatory markers).

OpenPayer